TRIUMEQ是哪里生产的？

Where is Suimeikai produced? TRIUMEQ is an innovative AIDS treatment drug produced by ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK). It is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerability, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby increasing patients' medication compliance and significantly improving their quality of life. So where is TRIUMEQ produced? Let's take a look.

According to Medical Partner Travel, the price of TRIUMEQ available in China is relatively expensive, and most patients cannot afford it. The price of TRIUMEQ in China is 2880$/month. Patients can choose to buy Suimeikai, which is available in India and is relatively cheap. Inbec, produced by the Indian company Emcure, has a box of 30 tablets and sells for about RMB 1,000.

Clinical data on TRIUMEQ are limited, and the most commonly reported adverse reactions that are possibly or probably related to dolutegravir and abacalongvir/lamivudine are nausea (12%), insomnia (7%), dizziness (6%), and headache (6%). Adverse reactions (nausea, vomiting, diarrhea, pyrexia, drowsiness, rash) occur frequently in patients with abacavir hypersensitivity reactions.

Patients experiencing the above symptoms should be carefully evaluated for the presence of this hypersensitivity reaction. Very rarely, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis have been reported and abacavir hypersensitivity cannot be excluded. In such cases, abacavir-containing medicinal products should be discontinued.

TRIUMEQ is based on DTG, an integrase inhibitor, as its core drug. In the real world, antiviral treatment-naïve patients treated with DTG are better than those of RAL (Ascent), DRV/r (darunavir), EFV (Etaton). The four drugs (Fiverenz) and ATV/r (Atazanavir) also have a lower proportion of central nervous system-related (CNS) adverse events. Therefore, the drug safety of Trimeq, which is based on DTG integrase inhibitors, has proven to be controllable.